Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line

被引:8
|
作者
Li, Hong
Cao, Hou-Fa
Wan, Jun
Li, Yuan
Zhu, Mei-Ling
Zhao, Po [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Nanlou Digest, Beijing 100853, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Inpatient Dept Med Hlth Ctr, Beijing 100853, Peoples R China
关键词
colonic adenocarcinoma; wild-type Kras2; cell cycle; apoptosis;
D O I
10.3748/wjg.v13.i6.934
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To observe the growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line Caco-2. METHODS: Recombinant plasmid pCI-neo-Kras2 with wild type Kras2 open reading frame was constructed. The Caco-2 cells were transfected with either pCI-neo or pCI-neo-Kras2 using Lipofectamine 2000. The expression of wild type Kras2 was examined by Northern blot analysis. And the expression of wild type Kras2 protein was examined by Western blot analysis. The effects of wild-type Kras2 on cell proliferation were analyzed by monotetrazolium (MTT) assay, meanwhile analyses of cell cycle and spontaneous apoptosis rate were carried out by flow cytometry (FCM). RESULTS: The plasmid of pCI-neo-Kras2 was successfully established. The growth rate of cells transfected with pCI-neo-Kras2 was significantly lower than the control cells transfected with the empty pCI-neo vector (P < 0.05). Cell cycle analysis revealed arrest of the pCI-neo-Kras2 transfected cells in G0/G1 phases, decreased DNA synthesis and decreased fractions of cells in S phase. The proliferative index of cells transfected with pCI-neo-Kras2 was decreased compared with the control cells (49.78% vs 64.21%), while the apoptotic rate of Caco-2 cells with stable Kras2 expression increased (0.30% vs 0.02%). CONCLUSION: The wild-type Kra52 gene effectively inhibits the growth of the colonic adenocarcinoma cell line Caco-2. (C) 2007 The WJG Press. All rights reserved.
引用
收藏
页码:934 / 938
页数:5
相关论文
共 50 条
  • [2] Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma
    Salem, Mohamed E.
    Al-hajeili, Marwan R.
    Dyson, Gregory
    Stanski, Natalja
    Jain, Tania
    Mahaseth, Hemchandra
    Choi, Minsig
    Shields, Anthony Frank
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] High sensitive mutation analysis on KRAS2 gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles
    Huang, Qing
    Wang, Gui-Yu
    Huang, Jun-Fu
    Zhang, Bo
    Fu, Wei-Ling
    MOLECULAR AND CELLULAR PROBES, 2010, 24 (06) : 376 - 380
  • [4] Immunotherapy Outcomes in KRAS Mutated vs KRAS Wild-Type Advanced Lung Adenocarcinoma
    Collons, D.
    Nguyen, R.
    Khan, M.
    Schwartz, C.
    Pasquinelli, M.
    Feldman, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S409 - S410
  • [5] Novel germ line mutations in the KRAS2 gene cause Noonan syndrome and deregulate hematopoietic cell growth.
    Schubbert, S
    Zenker, M
    Rowe, SL
    Böll, S
    Klein, C
    van der Burgt, I
    Musante, L
    Nguyen, H
    West, B
    Bollag, G
    Niemeyer, CM
    Shannon, KM
    Kratz, CR
    BLOOD, 2005, 106 (11) : 458A - 459A
  • [6] Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma
    Ambrogio, C.
    Kohler, J.
    Zhou, Z.
    Wang, H.
    Paranal, R.
    Capelletti, M.
    Caffarra, C.
    Li, S.
    Lv, Q.
    Gondi, S.
    Hunter, J.
    Chiarle, R.
    Santamaria, D.
    Westover, K.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2261 - S2261
  • [7] Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma
    Ambrogio, C.
    Kohler, J.
    Zhou, Z.
    Wang, H.
    Paranal, R.
    Capelletti, M.
    Caffarra, C.
    Li, S.
    Lv, Q.
    Santamaria, D.
    Westover, K. D.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma
    Ben-Ammar, I.
    Tarabay, A.
    Hollebecque, A.
    Tanguy, M.
    Boige, V.
    Malka, D.
    Smolenschi, C.
    Ducreux, M.
    Boileve, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S356 - S356
  • [9] Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
    Acosta Eyzaguirre, D. A.
    Fabregat-Franco, C.
    Castet, F.
    Lopez Valbuena, D. E.
    Castillo, G.
    Vega, S.
    Aguilar Izquierdo, S.
    Sierra, A.
    Tian, T.
    Vivancos, A.
    Dienstmann, R.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S910 - S910
  • [10] Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
    Philip, Philip A.
    Azar, Ibrahim
    Xiu, Joanne
    Hall, Michael J.
    Hendifar, Andrew Eugene
    Lou, Emil
    Hwang, Jimmy J.
    Gong, Jun
    Feldman, Rebecca
    Ellis, Michelle
    Stafford, Phil
    Spetzler, David
    Khushman, Moh'd M.
    Sohal, Davendra
    Lockhart, A. Craig
    Weinberg, Benjamin A.
    El-Deiry, Wafi k S.
    Marshall, John
    Shields, Anthony F.
    Korn, W. Michael
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2704 - 2714